ROCKET PHARMACEUTICALS, INC. (RCKT) - Dilution Analysis

10-Q filing | 112.1M shares outstanding

10-Q filing | 111.6M shares outstanding

10-Q filing | 111.0M shares outstanding

10-Q filing | 110.1M shares outstanding

10-K filing | 106.6M shares outstanding

8-K filing: Rocket Pharmaceuticals, Inc. completed an offering of 13,200,000 shares of common stock, with an additional 1,980,000 shares sold through the full exercise of the underwriters' option, at a public offering price of $12.50 per share, resulting in net proceeds of approximately $178.1 million. ($178.1M proceeds)

10-Q filing | 94.2M shares outstanding

10-Q filing | 93.7M shares outstanding

10-Q filing | 93.5M shares outstanding

10-K filing | 84.0M shares outstanding

10-Q filing | 82.6M shares outstanding

8-K filing: Rocket Pharmaceuticals, Inc. completed an offering of common stock and pre-funded warrants on September 15, 2023, raising approximately $188.9 million in net proceeds.

10-Q filing | 80.5M shares outstanding

10-Q filing | 79.5M shares outstanding

POS AM filing: This POS AM filing relates to a potential offering of Rocket Common Stock, with the price to be determined at the time of sale based on the method of sale and prevailing market price.

10-K filing | 79.3M shares outstanding

10-Q filing | 75.7M shares outstanding

8-K filing: Rocket Pharmaceuticals, Inc. entered into an underwriting agreement to issue and sell up to 7,820,000 shares of common stock at a public offering price of $14.75 per share, with net proceeds estimated to be approximately $94.0 million, or approximately $108.1 million if the Underwriters exercise in full their option. ($115.35M proceeds)

10-Q filing | 65.5M shares outstanding

10-Q filing | 64.5M shares outstanding

10-K filing | 63.2M shares outstanding

10-Q filing | 63.8M shares outstanding

S-3/A filing: The filing is for a shelf offering of common stock, preferred stock, and debt securities, warrants and/or units with a total proposed amount of $500,000,000.

8-K filing: Rocket Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with a fund affiliated with RTW Investments, LP, to sell 812,516 shares of common stock at $32.48 per share in a private placement for gross proceeds of approximately $26.4 million. ($26.4M proceeds)

10-Q filing | 63.1M shares outstanding

S-3/A filing: This is an S-3/A filing registering an indeterminate amount of common stock, preferred stock, debt securities, warrants, and units with an aggregate initial offering price not to exceed $500,000,000.

10-Q filing | 61.6M shares outstanding

8-K filing: Holders of approximately $38.35 million principal amount of the 6.25% Convertible Senior Notes due 2022 converted such Notes into approximately 1.3 million shares of the Company's common stock and cash in lieu of fractional shares.

S-3 filing: The company intends to offer and sell up to $500,000,000 of its common stock, preferred stock, debt securities, warrants and/or units, in any combination, together or separately.

10-K filing | 61.8M shares outstanding

8-K filing: Rocket Pharmaceuticals, Inc. completed an underwritten offering of 5,339,286 shares of common stock at a price of $56.00 per share, resulting in net proceeds of approximately $280.8 million, to be used for pipeline development, manufacturing buildout, and general corporate purposes.

10-Q filing | 55.2M shares outstanding

10-Q filing | 55.2M shares outstanding

10-Q filing | 55.2M shares outstanding

10-K filing | 55.1M shares outstanding

8-K filing: Rocket Pharmaceuticals, Inc. entered into exchange agreements to exchange $39.4 million of Old Notes for New Notes and cash, and repurchased 3,000 shares of its common stock for $71,670 from certain holders of the Old Notes. ($0.07M proceeds)